Worldwide CAR T-Cell Therapy Industry to 2030 – Players Include Legend Biotech, Novartis & Pfizer Among Others – PRNewswire

DUBLIN, Dec. 21, 2020 /PRNewswire/ -- The "Global CAR T-Cell Therapy Market: Focus on Product, Mechanism, Application, Target Antigen, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century. Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patient's immune system to attack cancer. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include increasing global geriatric population, increasing number of lymphoma and leukemia cases, rising number of relapsed or refractory cancer cases showing response failure to alternative treatments such as chemotherapy and radiation therapy, focus on research and development of novel immunotherapies, and strong product pipeline of global CAR T-cell therapy.

The market is favored by the development of CAR T-cell therapy for several clinical areas such as diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and other cancers or indications. The increase in the geriatric population and the increasing number of lymphoma and leukemia cases across the globe are expected to translate into significantly higher demand for the CAR T-cell therapy market.

Furthermore, the companies are investing huge amounts in research and development of CAR T-cell therapy either as a monotherapy or as combination therapy. The clinical trial landscape of various hematologic cancers has been on the rise in recent years, and this will fuel the CAR T-cell therapy market in the future.

Within the research report, the market is segmented based on application, target antigen, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel CAR T-cell therapy. Due to the diverse product portfolio and intense market penetration, Novartis AG. has been a pioneer in this field and has been a significant competitor in this market.

The pharmaceutical leading manufacturer, Kite Pharma, Inc. (a Gilead Company), has launched its CAR T-cell therapies into the market such as Yescarta (axicabtagene ciloleucel), and Tecartus (brexucabtagene autoleucel) to compete with Novartis AG's Kymriah (tisagenlecleucel) therapy market dominance.

Based on region, North America holds the largest share of the CAR T-cell therapy market due to improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Growth Drivers

Market Challenges

Market Opportunities

Key Questions Answered in this Report:

Key Topics Covered:

1 Technology Definition

2 Research Scope

3 Research Methodology

4 Market Overview4.1 Timeline of CAR T-Cell Therapy Development4.2 CAR T-Cell Therapy Market and Growth Potential, 2019-20304.3 CAR T-Cell Therapy and Clinical Trials Landscape4.3.1 Overview4.3.2 Clinical Trials in China4.3.3 Clinical Trials in Rest-of-the-World

5 Global CAR T-Cell Therapy Market, $Million, 2019-20305.1 Commercialized Therapeutics5.1.1 Tisagenlecleucel (Kymriah)5.1.2 Axicabtagene Ciloleucel (Yescarta)5.1.3 Brexucabtagene Autoleucel (Tecartus)5.2 Pipeline Therapeutics5.2.1 BB2121 (Idecaptagene Cicleucel)5.2.2 JCAR017 (Lisocabtagene Maraleucel)5.2.3 KTE-C19 (Axicabtagene Ciloleucel)5.2.4 CTL019 (Tisagenlecleucel)5.2.5 JNJ-682845285.3 Impact of COVID-19 - CAR T-Cell Therapy5.3.1 Impact of COVID-19 on Global CAR T-Cell Therapy Market Growth Rate5.3.2 Clinical Trial Disruptions and Resumptions5.3.3 COVID-19 Impact on Supply Chain of CAR T-Cell Therapy Market5.3.4 Reduced Diagnosis of Cancer5.3.5 Impact on Commercial Operations

6 CAR T-Cell Therapy Patent Landscape

7 Epidemiology of CAR T-Cell Therapy7.1 Overview7.2 CAR T-Cell Therapy Side-Effects7.2.1 Cytokine Release Syndrome (CRS)7.2.2 CAR T-Cell-Related Encephalopathy Syndrome (CRES)7.2.3 Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)7.3 Management of CAR T-Cell Therapy Side-Effects

8 Industry Insights8.1 Overview8.2 Regulatory Scenario of CAR T-Cell Therapy8.3 Legal Requirements and Frameworks in U.S.8.3.1 Clinical Trial Authorization8.3.2 Marketing Authorization8.3.3 USFDA Guidelines for BLA Submission8.3.4 Post-Authorization Regulations8.4 Legal Requirements and Frameworks in Europe8.4.1 EMA Biologics License Application Process8.4.2 Centralized Procedure8.4.3 Decentralized Procedure8.4.4 Mutual-Recognition Procedure8.4.5 National Procedure8.5 Legal Requirements and Frameworks in Asia-Pacific8.5.1 Regulation of Cell Immunotherapy in China8.5.2 Legal Requirements and Frameworks in Japan8.6 Expedited Regulatory Designations Around the World8.7 Pricing of CAR T-Cell Therapy8.8 Reimbursement of CAR T-Cell Therapy

9 CAR T-Cell Therapy Development and Manufacturing9.1 Overview9.2 Challenges in CAR T-Cell Therapy9.2.1 Therapy Approval9.2.2 Manufacture Quality Control9.2.3 Efficacy and Quality-Adjusted Life-Year (QALY) Assessment9.2.4 Safety Assessment9.2.5 Pricing and Patient Access9.2.6 Reimbursement

10 Market Dynamics10.1 Impact Analysis10.2 Market Drivers10.2.1 Rising Number of Patients with Hematologic Cancers10.2.2 Dramatic Rise in Global CAR T-Cell Trials10.2.3 Landmark Approvals of CAR T-Cell Therapies by USFDA and EMA10.3 Market Restraints10.3.1 High Treatment Cost of CAR T-Cell Therapy10.3.2 Side-Effects of CAR T-Cell Therapy10.4 Market Opportunities10.4.1 Opportunities for Immunotherapy

11 Global CAR T-Cell Therapy Market (by Application)11.1 Overview11.2 Diffuse Large B-Cell Lymphoma (DLBCL)11.3 Acute Lymphoblastic Leukemia (ALL)11.4 Multiple Myeloma (MM)11.5 Chronic Lymphocytic Leukemia (CLL)11.6 Follicular Lymphoma (FL)11.7 Mantle Cell Lymphoma (MCL)11.8 Others

12 Global CAR T-Cell Therapy Market (by Target Antigen)12.1 Overview12.2 CD19/CD2212.3 BCMA (B-Cell Maturation Antigen)12.4 Other Antigens

13 Global CAR T-Cell Therapy Market (by Region)13.1 Introduction13.2 North America13.2.1 U.S.13.2.1.1 U.S. CAR T-Cell Therapy Market (by Application), 2019-203013.2.2 Canada13.2.2.1 Canada CAR T-Cell Therapy Market (by Application), 2019-203013.3 Europe13.3.1 Germany13.3.1.1 Germany CAR T-Cell Therapy Market (by Application), 2019-203013.3.2 U.K.13.3.2.1 U.K. CAR T-Cell Therapy Market (by Application), 2019-203013.3.3 France13.3.3.1 France CAR T-Cell Therapy Market (by Application), 2019-203013.3.4 Italy13.3.4.1 Italy CAR T-Cell Therapy Market (by Application), 2019-203013.3.5 Spain13.3.5.1 Spain CAR T-Cell Therapy Market (by Application), 2019-203013.3.6 Rest-of-Europe13.3.6.1 Rest-of-Europe CAR T-Cell Therapy Market (by Application), 2019-203013.4 Asia-Pacific13.4.1 China13.4.2 Japan13.4.2.1 Japan CAR T-Cell Therapy Market (by Application), 2019-203013.4.3 India13.4.4 South Korea13.4.5 Australia13.4.5.1 Australia CAR T-Cell Therapy Market (by Application), 2019-203013.4.6 Rest-of-APAC13.4.6.1 Rest-of-APAC CAR T-Cell Therapy Market (by Application), 2019-203013.5 Latin America13.5.1 Brazil13.5.2 Mexico13.5.3 Rest-of-Latin America13.6 Rest-of-the-World

14 Competitive Landscape14.1 Key Developments and Strategies14.1.1 Overview14.1.1.1 Regulatory and Legal Developments14.1.1.2 Partnerships, Alliances, and Business Expansions14.1.1.3 M&A Activities14.1.1.4 Funding Activities14.2 Market Share Analysis

15 Company Profiles15.1 Overview15.2 Amgen, Inc.15.2.1 Company Overview15.2.2 Role of Amgen, Inc. in Global CAR T-Cell Therapy Market15.2.3 Financials15.2.4 R&D Expenditure, 2017-201915.2.5 SWOT Analysis15.3 Autolus Therapeutics plc15.4 Bellicum Pharmaceuticals, Inc.15.5 Bluebird Bio Inc15.6 Bristol-Myers Squibb Company15.7 CARsgen Therapeutics, Ltd.15.8 Cartesian Therapeutics, Inc.15.9 Cellectis S.A.15.1 Celyad Oncology SA15.11 Fortress Biotech, Inc15.12 Janssen Pharmaceuticals, Inc.15.13 Kite Pharma, Inc (A Gilead Company)15.14 Legend Biotech Corporation15.15 Novartis AG15.16 Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/r/sywmmz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more from the original source:
Worldwide CAR T-Cell Therapy Industry to 2030 - Players Include Legend Biotech, Novartis & Pfizer Among Others - PRNewswire